within Pharmacolibrary.Drugs.ATC.L;

model L03AX22
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.74,
    Cl             = 14.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 70 / 1000000,
    adminCount     = 1,
    Vd             = 0.022699999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0125,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Leniolisib is an oral selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, used for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency disorder. It is approved for use in the United States and the European Union in patients aged 12 years and older with APDS.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for leniolisib reported in APDS patients (male and female, ages 12 and older) after oral administration of a 70 mg twice daily dose.</p><h4>References</h4><ol><li><p>Pearson, D, et al., &amp; Walles, M (2019). . <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 49(8) 953–960. DOI:<a href=&quot;https://doi.org/10.1080/00498254.2018.1523488&quot;>10.1080/00498254.2018.1523488</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30215545/&quot;>https://pubmed.ncbi.nlm.nih.gov/30215545</a></p></li><li><p>De Buck, S, et al., &amp; Woessner, R (2018). CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib. <i>Biopharmaceutics &amp; drug disposition</i> 39(8) 394–402. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2157&quot;>10.1002/bdd.2157</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30171694/&quot;>https://pubmed.ncbi.nlm.nih.gov/30171694</a></p></li><li><p>Rao, VK, et al., &amp; Burkhart, C (2017). Effective &quot;activated PI3Kδ syndrome&quot;-targeted therapy with the PI3Kδ inhibitor leniolisib. <i>Blood</i> 130(21) 2307–2316. DOI:<a href=&quot;https://doi.org/10.1182/blood-2017-08-801191&quot;>10.1182/blood-2017-08-801191</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28972011/&quot;>https://pubmed.ncbi.nlm.nih.gov/28972011</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L03AX22;
